Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720

Keyphrases

• Nonhuman Primate 100%
• Islet Allograft 100%
• Immunosuppressed 100%
• Allograft Survival 100%
• Basiliximab 100%
• FTY720 100%
• Insulin Independence 66%
• C-peptide Levels 66%
• Clinical Trials 33%
• Immunosuppression 33%
• Diabetic 33%
• Islet Transplantation 33%
• Everolimus 33%
• Maintenance Immunosuppression 33%
• Calcineurin Inhibitors 33%
• Type 1 Diabetic 33%
• Transplantation 33%
• Transplantation Therapy 33%
• Lymphocytes 33%
• Arginine 33%
• Corticosteroids 33%
• Islet Autotransplant 33%
• Cynomolgus Monkey 33%
• Pretransplant 33%
• C-peptide 33%
• Streptozotocin-induced 33%
• Immunosuppressive Therapy 33%
• Postoperative Day 33%
• Infectious Complications 33%
• Blood Glucose 33%
• Exogenous Insulin 33%
• Blood Levels 33%
• ABO Incompatibility 33%
• Islet Equivalent 33%
• Insulin Requirement 33%
• Induction Immunosuppression 33%
• C-peptide Response 33%
• Transplantation Model 33%
• Subtherapeutic 33%
• Adverse Complications 33%

Immunology and Microbiology

• Fingolimod 100%
• Basiliximab 100%
• Allograft 100%
• Insulin 100%
• Immunosuppression 75%
• Peptides 75%
• Immunosuppressive Drug 25%
• Everolimus 25%
• Immunosuppressive Therapy 25%
• Macaca fascicularis 25%
• Glucose Blood Level 25%
• Blood Level 25%
• Lymphocyte 25%
• Arginine 25%

Pharmacology, Toxicology and Pharmaceutical Science

• C Peptide 100%
• Basiliximab 100%
• Fingolimod 100%
• Immunosuppressive Agent 66%
• Diabetes Mellitus 66%
• Clinical Trial 33%
• Macaca fascicularis 33%
• Streptozotocin 33%
• Everolimus 33%
• Calcineurin Inhibitor 33%
• Adverse Event 33%
• Infectious Complication 33%
• Arginine 33%